Anthropic Used Claude Model in Drug Development Studies

Anthropic shared the first studies of its Claude artificial intelligence model in the field of drug development. While various findings were obtained in areas such as cancer, food allergies, and rare diseases in projects conducted with six organizations, the effects of the studies on humans are not yet known.

Anthropic announced the first projects in which the Claude model was used in drug development processes. It is aimed to utilize Claude in stages such as preparing experiments, examining results, and writing reports during the drug development process. In this context, the Generate Biomedicines team redesigned CAR-T cells used in cancer treatment, shortening a part of the genetic code of the receptor in the cells by 70 percent and increasing the number of cancer-recognizing receptors 10-fold in laboratory tests.

Claude also designed 35,000 antibodies targeting food allergies for Divergence Labs, and some candidates yielded positive results in initial tests. While BigHat Biosciences developed antibody fragments that bind more strongly to the target and are more heat resistant with the help of artificial intelligence, Enveda reduced report review time from 26 hours to 3 hours. While Bristol Myers Squibb used Claude to evaluate clinical research plans, company executive Michael Pourdehnad stated that he prepared a preliminary review that normally takes days with a single command. Mithril Medicine, acquired by Anthropic, continues to research treatments for two rare muscle diseases in mice.